Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis

Inclusion Criteria: * Age ≥18 and ≤80 years; * Symptomatic intracranial atherosclerotic stenosis patients with ineffective medical treatment; * Digital subtraction angiography (DSA) shows target lesion stenosis ≥70%; * Suitable for implantation of rapamycin-targeted drug-eluting stents; * The patient and/or their authorized representative can understand the study purpose, agree to participate, and sign the informed consent form. Exclusion Criteria: * Modified Rankin Scale (mRS) score ≥3; * Ischemic stroke within the past 2 weeks; * Presence of more than 2 intracranial atherosclerotic stenosis lesions requiring interventional treatment; * Severe contraindications to heparin, aspirin, ticagrelor, clopidogrel, or other antiplatelet drugs, and inability to tolerate anticoagulant/antiplatelet therapy; * Severe dysfunction of major organs (e.g., severe hepatic insufficiency, renal insufficiency, heart failure); * Severe allergies to contrast agents, rapamycin and its derivatives, cobalt-based alloys, or polylactic acid; * Pregnant or lactating women; * Participation in other drug or device studies without reaching the endpoint; * Life expectancy less than 12 months; * Lesions or vascular access deemed unsuitable for rapamycin drug-eluting stent implantation by the operator.